CONFERENCES

      Lung in vitro Event for Innovative and Predictive Models

      Lung in vitro event for innovative and predictive models, or LIVe, is an annual conference that focuses on in vitro studies of respiratory models, with topics ranging from inhalation toxicity testing to airway/lung on a chip. The event is aimed at stakeholders from academia, pharma, biotech, chemical, tobacco, consumer goods, medical devices industries, and regulatory agencies, and provides a forum for sharing knowledge and collaborating on the future development and use of in vitro lung models.

      LIVe 2022

      Date

      Jun 13, 2022 - Jun 14, 2022

      Location

      Nice, France

      LIVe2022 intends to be an exchange platform for scientists interested in in vitro respiratory researches, stakeholders from academia, pharma, biotech, chemical, tobacco, consumer goods, medical devices industries, CROs and regulatory agencies. The meeting will focus on predictive in vitro lung models designed for basic research, efficacy and toxicity testing. It aims to present the state-of-art of in vitro lung models, and to map out the route for its future development and use. 

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.